Provided by Tiger Trade Technology Pte. Ltd.

TEMA ONCOLOGY ETF

44.16
+0.48401.11%
Volume:15.63K
Turnover:689.66K
Market Cap:213.75M
PE:- -
High:44.79
Open:43.99
Low:43.67
Close:43.68
52wk High:47.00
52wk Low:26.62
Shares:4.84M
Float Shares:4.84M
Volume Ratio:0.71
T/O Rate:0.32%
Dividend:0.02
Dividend Rate:0.04%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Revolution Medicines to Charge $39,800 a Month for Pancreatic Cancer Drug, Bloomberg Reports

MT Newswires Live
·
Aug 27

Revolution Medicines - Rasonque is NOW Commercially Available in the U.S. at a Wholesale Acquisition Cost of $39,800 for a 30-Day Supply - Conf Call

THOMSON REUTERS
·
Aug 27

Revolution Medicines Posts Investor Presentation on Rasonque FDA Approval

Reuters
·
Aug 27

Revolution Medicines prices Rasonque at $39,800 for 30-day supply

TIPRANKS
·
Aug 27

Revolution Medicines announces FDA approval of Rasonque in adults

TIPRANKS
·
Aug 27

Revolution Medicines, - Rasonque 300 Mg Once-Daily Oral Tablets NOW Available in the U.S.

THOMSON REUTERS
·
Aug 27

U.S. FDA Approves Revolution Medicines’ Rasonque™ (Daraxonrasib), the First Broad Ras-Targeted Medicine in Metastatic Pancreatic Cancer

THOMSON REUTERS
·
Aug 27

U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer

GlobeNewswire
·
Aug 27

Eli Lilly Expands Alzheimer’s Pipeline With New Amyloid Phase 1 Trial

TIPRANKS
·
Aug 27

Eli Lilly Stock (LLY) in Focus as Alzheimer’s Blood Test Gets FDA Approval

TIPRANKS
·
Aug 26

FDA Approves Drug for Pancreatic Cancer in Incredible Moment for Deadly Disease

Dow Jones
·
Aug 26

US FDA Approves Revolution Medicines' Pancreatic Cancer Drug

Reuters
·
Aug 26

FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer

THOMSON REUTERS
·
Aug 26

Eli Lilly and Co Stock (LLY) Opened Down by 3.57% on Aug 26: Facts Behind the Movement

TradingKey
·
Aug 26

Eli Lilly Study Shows Lower Healthcare Costs With Zepbound in Older Adults

MT Newswires Live
·
Aug 26

Revolution Medicines CEO Mark A. Goldsmith Reports Disposal of Common Shares Worth $16.87 Million

Reuters
·
Aug 26

Zepbound Linked to Lower Healthcare Costs in Adults over Age 55 with Obesity According to a Real-World Study

THOMSON REUTERS
·
Aug 26

Sweden's BioArctic Q2 Revenue Falls Despite Higher Leqembi Royalties

Reuters
·
Aug 26

AlzeCure Swings to Q2 FY26 Profit of SEK 80.18 Million; Net Sales Rise to SEK 97.33 Million

Reuters
·
Aug 26

Eli Lilly (LLY) Stock Trades Below Fair Value On Cash Flow

Simply Wall St.
·
Aug 26